| 1052.19995 30.18 (2.95%) | 02-27 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1245.34 | 1-year : | 1298.98 |
| Resists | First : | 1066.21 | Second : | 1112.14 |
| Pivot price | 1033.26 |
|||
| Supports | First : | 991.92 | Second : | 825.28 |
| MAs | MA(5) : | 1039.39 |
MA(20) : | 1035.15 |
| MA(100) : | 994.12 |
MA(250) : | 859.5 |
|
| MACD | MACD : | -3.5 |
Signal : | -4.5 |
| %K %D | K(14,3) : | 28.3 |
D(3) : | 32.3  |
| RSI | RSI(14): 51.4 |
|||
| 52-week | High : | 1132.06 | Low : | 620.46 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LLY ] has closed below upper band by 28.6%. Bollinger Bands are 55.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1028.05 - 1036.42 | 1036.42 - 1042.05 |
| Low: | 989.92 - 999.2 | 999.2 - 1005.44 |
| Close: | 1009.79 - 1024.26 | 1024.26 - 1033.98 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Sat, 28 Feb 2026
A Look At Eli Lilly (LLY) Valuation After GLP‑1 Trial Wins And Obesity Franchise Progress - simplywall.st
Sat, 28 Feb 2026
Eli Lilly Stock (LLY) Opinions on FDA GLP-1 Side Effect Update - Quiver Quantitative
Sat, 28 Feb 2026
Eli Lilly stock price rebounds above $1,050 — what traders are watching next - TechStock²
Sat, 28 Feb 2026
Eli Lilly and Company $LLY Shares Purchased by Rafferty Asset Management LLC - MarketBeat
Sat, 28 Feb 2026
Eli Lilly and Company $LLY Shares Bought by Power Wealth Management LLC - MarketBeat
Fri, 27 Feb 2026
RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 943 (M) |
| Held by Insiders | 8.9097e+008 (%) |
| Held by Institutions | 0.3 (%) |
| Shares Short | 6,970 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.169e+010 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 51.4 |
| Profit Margin | 0 % |
| Operating Margin | 31.6 % |
| Return on Assets (ttm) | 44.9 % |
| Return on Equity (ttm) | 19.4 % |
| Qtrly Rev. Growth | 6.518e+010 % |
| Gross Profit (p.s.) | 109.23 |
| Sales Per Share | 259.38 |
| EBITDA (p.s.) | 1.38795e+011 |
| Qtrly Earnings Growth | 22.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 16,810 (M) |
| PE Ratio | 0 |
| PEG Ratio | 24.1 |
| Price to Book value | 20.33 |
| Price to Sales | 4.03 |
| Price to Cash Flow | 13.74 |
| Dividend | 0 |
| Forward Dividend | 6.98e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|